Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Vote in favor of your #1 Kind of Cap - 2Medical team successfully delivers baby and removes massive tumor
- 3Gaza amputees struggle to rebuild lives as the enclave faces shortages of prosthetic limbs
- 4From Exemplary to Current: Famous Rings Available
- 5Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
- Kona SUV: The Courageous Minimized That is Catching Hearts Around the world
- Exploring ways to reduce the impact of space junk on Earth
- Find Successful Magnificence Items for Sparkling Skin
- Man triggers smoke bomb during failed crypto robbery
- Become the best at Discussion: 6 Procedures for Progress
- Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- Figure out How to Put resources into Lab Precious stones
- Famous Rough terrain Vehicles for 2024
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
